Muutke küpsiste eelistusi

Contemporary Issues in Pharmaceutical Patent Law: Setting the Framework and Exploring Policy Options [Kõva köide]

Edited by , Edited by (Chinese University of Hong Kong)
  • Formaat: Hardback, 258 pages, kõrgus x laius: 234x156 mm, kaal: 640 g, 5 Tables, black and white; 5 Illustrations, black and white
  • Sari: Routledge Research in Intellectual Property
  • Ilmumisaeg: 16-Feb-2017
  • Kirjastus: Routledge
  • ISBN-10: 1138934488
  • ISBN-13: 9781138934481
Teised raamatud teemal:
  • Formaat: Hardback, 258 pages, kõrgus x laius: 234x156 mm, kaal: 640 g, 5 Tables, black and white; 5 Illustrations, black and white
  • Sari: Routledge Research in Intellectual Property
  • Ilmumisaeg: 16-Feb-2017
  • Kirjastus: Routledge
  • ISBN-10: 1138934488
  • ISBN-13: 9781138934481
Teised raamatud teemal:

Developed and developing country governments around the world often struggle to provide prompt and affordable access to medicines for the populace and so maintain proper levels of health care at affordable prices. This collection explores the complexities associated with the intersection of pharmaceutical law and policy and public health. Focusing on patent and relevant regulatory laws, the collection provides a comprehensive overview of the most important and pressing issues governments are currently facing in regards to ensuring access to medicines at an affordable cost. Each chapter focuses on a separate issue and offers clear, balanced and detailed analysis of the international framework, trends and available policy options.

Throughout, the volume emphasises the need for governments to think and act in a systemic manner and break away from the ‘silo’ method of dividing responsibilities between various government departments. The book sets out ways in which law and policy in the area of pharmaceutical patents, health and policy can be integrated in order to ensure coherence and regulatory predictability.

Arvustused

'The editors have mustered a wide range of authors, including legal practitioners, academics and a Constitutional Court Justice, to opine on a broad range of topical issues confronting rule-makers concerning pharmaceutical patent law. This diversity makes for a varied discussion.'

John A. Tessensohn, European Intellectual Property Review

'A solid reference book for scholars and those interested in governments struggle between incentivising innovation and access to affordable medicine.'



John A. Tessensohn, European Intellectual Property Review

Notes on Contributors vii
1 Introduction: A Holistic Approach to Pharmaceutical Patent Law and Policy
1(6)
Bryan Mercurio
Daria Kim
PART I Pharmaceutical Patents and Related Types of Protection
7(116)
2 Patentability of Pharmaceutical Inventions under TRIPS: Domestic Court Practice Testing International Policy Space
9(38)
Roberto Romandini
Henning Grosse Ruse Khan
3 Biologics, Biosimilars and Other Idiosyncrasies
47(21)
Yaniv Heled
4 Index of Data Exclusivity and Access (IDEAS): An Analysis of Test Data Exclusivity Provisions in Free Trade Agreements and National Laws
68(29)
Owais Hassan Shaikh
5 Patent Linkage Regulations: The Importance of Context and of Balancing Competing Interests
97(26)
Bryan Mercurio
PART II Balancing Patent Protection with Available Flexibilities
123(64)
6 The Bolar Exception: Legislative Models and Drafting Options
125(19)
Carlos Correa
7 Compulsory Licensing: Threats, Use and Recent Trends
144(17)
Chang-Fa Lo
8 A Manufacturing for Export Exception
161(26)
Xavier Seuba
Luis Mariano Genovesi
Pedro Roffe
PART III A Broader View on Incentives for Pharmaceutical Innovation
187(54)
9 The Price of Exclusivity: The Economics of Patent Extensions and Data Protection
189(14)
Aidan Hollis
Paul Grootendorst
10 Rationalizing Innovation Incentives under Drug Approval Regulation: National Policy Perspective
203(22)
Daria Kim
11 The Trans-Pacific Partnership Agreement and Its Implications for Access to Medicine
225(16)
Jakkrit Kuanpoth
Index 241
Bryan Mercurio is Professor and Vice Chancellor's Outstanding Fellow of the Faculty of Law at the Chinese University of Hong Kong.



Daria Kim is Doktorandin at the Max Planck Institute for Innovation and Competition.